182 related articles for article (PubMed ID: 2012752)
21. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.
Nand S; Sosman J; Godwin JE; Fisher RI
Blood; 1994 Jan; 83(2):357-60. PubMed ID: 8286736
[TBL] [Abstract][Full Text] [Related]
23. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
Runde V; Aul C; Ebert A; Grabenhorst U; Schneider W
Eur J Haematol; 1995 Jan; 54(1):39-45. PubMed ID: 7859874
[TBL] [Abstract][Full Text] [Related]
24. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
26. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
[TBL] [Abstract][Full Text] [Related]
27. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.
Höffken K; Overkamp F; Stirbu J; Grothey A; Flasshove M; Hoelzer D; Ganser A
Onkologie; 1990 Feb; 13(1):33-7. PubMed ID: 2186322
[TBL] [Abstract][Full Text] [Related]
29. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
Nagler A; Binet C; Mackichan ML; Negrin R; Bangs C; Donlon T; Greenberg P
Blood; 1990 Oct; 76(7):1299-307. PubMed ID: 1698477
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
32. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
[TBL] [Abstract][Full Text] [Related]
33. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia.
Gradishar WJ; Le Beau MM; O'Laughlin R; Vardiman JW; Larson RA
Blood; 1992 Nov; 80(10):2463-70. PubMed ID: 1421369
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.
Anderson H; Gurney H; Thatcher N; Swindell R; Scarffe JH; Weiner J
Recent Results Cancer Res; 1991; 121():155-61. PubMed ID: 1650015
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
J Clin Oncol; 1989 Feb; 7(2):159-67. PubMed ID: 2644395
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex.
Levine JD; Allan JD; Tessitore JH; Falcone N; Galasso F; Israel RJ; Groopman JE
Blood; 1991 Dec; 78(12):3148-54. PubMed ID: 1742482
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
[TBL] [Abstract][Full Text] [Related]
38. Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent thrombocytopenia.
Vesole DH; Jagannath S; Glenn LD; Barlogie B
Am J Hematol; 1994 Nov; 47(3):203-7. PubMed ID: 7942785
[TBL] [Abstract][Full Text] [Related]
39. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.
Rose C; Wattel E; Bastion Y; Berger E; Bauters F; Coiffier B; Fenaux P
Leukemia; 1994 Sep; 8(9):1458-62. PubMed ID: 8090025
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
Steward WP; Scarffe JH; Austin R; Bonnem E; Thatcher N; Morgenstern G; Crowther D
Br J Cancer; 1989 Jan; 59(1):142-5. PubMed ID: 2667607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
